Marijuana is now legal in many places, but is it safe? Two new studies add to mounting evidence that people who use cannabis are more likely to suffer a heart attack than people who do not use the ...

ACC's October Board of Trustees (BOT) meeting was rich with strategic dialogue and forward-looking initiatives that reflect our shared commitment to advancing cardiovascular care and strengthening the ...

Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves symptoms in men and women with a common type of heart failure that has had few therapeutic options ...

The One Big Beautiful Bill Act (OBBBA) became law on July 4, cutting more than $1 trillion in Medicaid funding and making substantial changes to the federal student loan program. When the U.S. House ...

The U.S. Food and Drug Administration (FDA) has approved acoramidis as a treatment to help reduce cardiovascular death and cardiovascular-related hospitalization in patients with transthyretin amyloid ...

The Centers for Medicare and Medicaid Services (CMS) released the 2025 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgery Center (ASC) final rule on Nov. 1. The rule will ...

The U.S. Food and Drug Administration has approved on April 2 the Abbott TriClip™, a transcatheter edge-to-edge repair (TEER) system specifically designed for the treatment of tricuspid regurgitation ...

Consumption of ultra-processed foods, such as sugar-sweetened beverages, breads, potato chips and packaged cookies, may be associated with adverse health outcomes, including hypertension, cancer, ...

The ACC is excited to announce that two of its JACC Journals – JACC: Asia and JACC: Advances – will receive an official Impact Factor, with the first rankings being issued in June 2026 as part of the ...

In this week’s View, Dr. Eagle looks at the social drivers behind the rise in heart disease mortality in California. He then explores the prevalence of preexisting cardiometabolic comorbidities and ...

Findings from the PREVUE-VALVE study presented at TCT 2025 shed light on the prevalence of valvular heart disease (VHD) and its subtypes among older Americans, as well as the influence of age, sex, ...

Semaglutide, the popular anti-obesity medication originally developed to treat diabetes, continues to show cardiovascular benefits beyond weight loss, including reducing risk of death, reducing ...